ArticleNeoplasia (New York, N.Y.)2011

The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.

Annet Kirabo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.